Multiple endocrine neoplasias. Recent advances in clinical and genetic diagnosis;Néoplasies endocriniennes multiples. Quand et comment les rechercher? Apports récents de la génétique

Revue de Medecine Interne

Volumn 24, Issue 11, 2003, Pages 721-729

  Bauters, C ^a   Leclerc, L ^a   Wemeau J L ^a   Proye, C ^a   Pigny, P ^a   Porchet, N ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

FMTC; Genetic testing; MEN 1; MEN 2

Indexed keywords

PROTEIN TYROSINE KINASE;

ADRENAL CORTEX ADENOMA; AUTOSOMAL DOMINANT DISORDER; BRONCHUS CARCINOID; EARLY DIAGNOSIS; FAMILIAL CANCER; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; HYPOPHYSIS ADENOMA; LIPOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; ONCOGENE RET; PANCREAS ISLET CELL TUMOR; PHEOCHROMOCYTOMA; PRIMARY HYPERPARATHYROIDISM; REVIEW; SIPPLE SYNDROME; THYMOMA; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0242596450     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00212-1     Document Type: Review

References (63)

1. Calender A, Gaudray P, Giraud S, Murat A, Zhang CX. GENEM. Néoplasie endocrinienne multiple de type 1: du syndrome au gène, du gène aux syndromes. Med Ther 1998;4:147-56.
2. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid. Am J Med 1961;31:163-6.
3. Gorlin RJ, Sedano HO, Vickers RA, Cervenja J. Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid: a syndrom. Cancer 1968;22:293-6.
4. Farndon JR, Leight GS, Dilley WG. Familial medullary thyroid carcinoma without associated endocrinopathies: a new clinical entity. Br J Surg 1986;73:278-81.
5. Chanson P, Murat A, Cadiot G, Calender A. Néoplasie endocrinienne multiple de type 1. Mt endocrinologie 1999;1:244-55.
6. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001;12:173-8.
7. Shepherd JJ. The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch Surg 1991;126:935-52.
8. Skogseid B, Rastad J, Oberg K. Multiple endocrine neoplasia type 1. Clinical features and screening. Endocrinol Metab Clin North Am 1994;23:1-18.
9. Benson L, Ljunghall S, Akerstrom G, Oberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am J Med 1987;82:731-7.
10. Waterlot C, Bauters C. Les tumeurs digestives endocrines dans les néoplasies endocriniennes multiples de type 1. Rev Fr Endocrinol Clin 1998;39:23-33.
11. Schepherd JJ, Challis DR, Davies PF, McArdle J, Teh BT, Wilkinson S. Multiple endocrine neoplasm, type 1. Gastrinomas, pancreatic neoplasms, microcarcinoids, the Zollinger-Ellison syndrome, lymph nodes, and hepatic metastases. Arch Surg 1993;128:1133-42.
12. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemichal, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 1996;81:2642-6.
13. Verges B, Boureille F, Goudet P, Murar A, Beckers A, Sassolas G, et al. Pituitary disease in MEN type 1 (MEN 1): data from the France-Belgium MEN 1 multicenter study. J Clin Endocrinol Metab 2002;87:457-65.
14. Burgess JR, Harle RA, Tucker P, Parameswaran V, Davies P, Greenaway, et al. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 1996;131:699-702.
15. Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad L, Theodorsson E, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992;75:76-81.
16. Duh QY, Hybarger CP, Geist R, Gamsu G, Goodman PC, Gooding GA, et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg 1987;154:142-8.
17. Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997;133:853-7.
18. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-7.
19. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997;276:404-7.
20. The European Consortium on MEN1. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997;6:1177-83.
21. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, et al. Menin, the poduct of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998;95:1630-4.
22. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activation transcription. Cell 1999;96:143-52.
23. Calender A, Vercherat C, Cordier M. Le gène de la ménine (NEM1) et la physiopathogénie des tumeurs neuro-endocrines digestives associées à la NEM1. Med Hyg 2001;59:1654-62.
24. Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-75.
25. Basset JH, Forbes SA, Pannet AA, Lloyd SE, Christie PT, Wooding C, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232-44.
26. Giraud S, Zhang CX, Serova-Sinilnikova O, Wautot V, Salandre J, Buisson N, et al. Germline mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 1998;63:455-67.
27. Teh BT, Kytola S, Farnebo F, Bergman L, Wong FK, Weber G, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly, and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2621-6.
28. The European Consortium on MENI. Linkage disequilibrium studies in multiple endocrine neoplasia type 1 (MEN1). Hum Genet 1997;100:657-65.
29. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
30. Chanson P, Cadiot G, Murat A. Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN1. GENEM1. Horm Res 1997;47:211-20.
31. Waterlot C, Porchet N, Bauters C, Decoulx M, Wémeau JL, Proye C, et al. Type 1 multiple endocrine neoplasia (MEN1): contribution of genetic analysis to the screening and follow-up of a large French kindred. Clin Endocrinol 1999;51:101-7.
32. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrom. Nat Genet 2002;32:676-80.
33. Zimmer T, Scherubl H, Faiss S, Stolzel U, Riecken EO, Wiedenmann B. Endoscopic ultrasonography of neuro-endocrine tumours. Digestion 2000;62(Suppl 1):45-50.
34. Proye C. Endocrine tumors of the duodenum and pancreas: "prerequisites", imaging, and intra-operative detection. Ann Chir 2001;126:290-5.
35. Conte-Devolx B, Niccoli-Sire P. Néoplasies endocriniennes multiples de type 2. Encycl Med Chir (Elsevier, Paris), Endocrinologie-Nutrition 1999;10-036-A-08:6p.
36. Bauters C, Waterlot C. Les phéochromocytomes des néoplasies endocriniennes multiples de type 2. Rev Fr Endocrinol Clin 1998;39:35-43.
37. Casanova S, Rosenberg-Bourgin M, Farkas D, Calmettes C, Feingold N, Hehmati HM, et al. Pheochromocytoma in multiple endocrine neoplasia type 2A: a survey of 100 cases. Clin Endocrinol 1993;38:531-7.
38. Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen study group. J Intern Med 1995;238:363-7.
39. Nguyen L, Niccoli-Sire P, Caron P, Bastie D, Maes B, Chabrier G, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. Eur J Endocrinol 2001;144:37-44.
40. Kraimps J, Denisot A, Carnaille B, Henry JF, Proye C, Bacourt F, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A: a retrospective french multicentric study. World J Surg 1996;20:808-13.
41. Mathew CGP, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987;328:527-8.
42. Mulligan LM, Kwok LBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
43. Chiefari E, Russo D, Giuffrida D, Meringolo D, Arturi F, Chiodini I, et al. Analysis of RET proto-oncogene abnormalities in patients with MEN2A, MEN2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest 1998;21:358-64.
44. Cote GJ, Wohllk N, Evans D, Goepfert H, Gagel RF. RET protooncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillieres Clin Endocrinol Metab 1995;9:609-30.
45. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET protooncogene are associated with MEN2A and FMTC. Hum Molecular Genet 1993;2:851-6.
46. Marsh DJ, Mulligan LM, Eng C. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Horm Res 1997;47:168-78.
47. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet M, Calmettes C, et al. RET proto-oncogene mutations in French MEN2A and FMTC families. Hum Mol Genet 1994;3:1939-43.
48. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1995;80:3088-90.
49. Pigny P, Bauters C, Wémeau JL, Lecomte-Houcke M, Crépin M, Caron P, et al. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:1700-4.
50. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium Analysis. JAMA 1996;276:1575-9.
51. Gagel RF, Cote GJ, Martins Bugalho MJ, Boyd AE, Cummings T, Goepfert H, et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med 1995;238:333-41.
52. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC. Nature Genet 1994;6:70-4.
53. Mulligan LM, Marsh DJ, Robinson DG, Schuffenecker I, Zedenius J, Lips CJ, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the international RET mutation consortium. J Intern Med 1995;238:343-6.
54. Jonston LB, Chew SL, Lowe D, Reznek R, Monson JP, Savage MO. Investigating familial endocrine neoplasia syndromes in children. Horm Res 2001;55:31-5.
55. Jonhston LB, Chew SL, Trainer PJ, Reznek R, Grossman AB, Besser GM, et al. Screening children at risk of developing inherited endocrine neoplasia syndromes. Clin Endocrinol 2000;52:127-36.
56. Phay JE, Moley JF, Lairmore TC. Multiple endocrine neoplasias. Semin Surg Oncol 2000;18:324-32.
57. Conte-Devolx B, Schuffenecker I, Niccoli P, Maes B, Boneu A, Barbot N, et al. Multiple endocrine neoplasia type 2: management of patients and subjects at risk. Horm Res 1997;47:221-6.
58. Heshmati HM, Hofbauer LC. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. Eur J Endocrinol 1997;137:572-8.
59. Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne JC, et al. Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. Eur J Endocrinol 1999;141:563-9.
60. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancusi F, et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 1995;118:1031-5.
61. Sanso GE, Domene HM, Garcia Rudaz MC, Pusiol E, de Mondino AK, Roque M. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children. Presence of C-cell malignant disease in asymptomatic carriers. Cancer 2002;94:323-30.
62. Wells SA, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowston SB, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2a. Ann Surg 1994;220:237-50.
63. Barbot N, Calmettes C, Schuffenecker I, Saint-André JP, Franc B, Rohmer V, et al. Pentagastrin stimulation test and early diagnosis of medullary carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:114-20.